.png | CAS_number = 129497-78-5 | ATC_prefix = L01 | ATC_suffix = XD02 | ATC_supplemental = | PubChem = 5362420 | DrugBank = APRD01290 | chemical_formula = C₄₁H₄₂N₄O₈ | molecular_weight = 718.794 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }} Verteporfin, otherwise known as benzoporphyrin derivative (Visudyne®), is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelenght of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Administration

---

Verteporfin is given intravenously, within 15 minutes before laser treatment.

Side effects

---

Most commonly, blurred vision. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin.